An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia
Sleep MedicinePublished 18 October 2005
Thomas Röth, Jared P. Walsh, Andrew D. Krystal, Thomas Wessel, Timothy Roehrs
Citations225
SJR quartileQ1
SJR score1.23
SNIP1.24
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Significant improvements in sleep and daytime function were evident in those switched from double-blind placebo to 6 months of open-label eszopiclone therapy and were sustained during the 6 years ofopen-label treatment for those receiving prior double- blind eszopylone.
Abstract
The significant improvements in sleep and daytime function were evident in those switched from double-blind placebo to 6 months of open-label eszopiclone therapy and were sustained during the 6 months of open-label treatment for those receiving prior double-blind eszopiclone. During 12 months of nightly treatment, eszopiclone 3mg was well tolerated; tolerance was not observed.
Keywords
PsychologyNeuroscience
JAMAEpidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?
2,453 Citations1989Daniel E. Ford
Biological PsychiatrySleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults
1,828 Citations1996Naomi Breslau, Thomas Roth +2 more
Prior insomnia remained a significant predictor of subsequent major depression when history of other prior depressive symptoms was controlled for, and complaints of 2 weeks or more of insomnia nearly every night might be a useful marker of subsequent onset of major depression.
JAMABehavioral and Pharmacological Therapies for Late-Life Insomnia
1,088 Citations1999Charles M. Morin, Cheryl Colecchi +3 more
Behavioral and pharmacological approaches are effective for the short-term management of insomnia in late life; sleep improvements are better sustained over time with behavioral treatment.
Archives of General PsychiatryInsomnia and Its Treatment
1,065 Citations1985Glen D. Mellinger
The survey found that insomnia afflicts 35% of all adults during the course of a year; about half of these persons experience the problem as serious; the majority of serious insomniacs were untreated by either prescribed or over-the-counter medications.
PubMedCharacteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.
781 Citations1999Sonia Ancoli‐Israel, Thomas Roth
The National Sleep Foundation in conjunction with the Gallup Organization conducted telephone interviews with a sample of Americans to examine the prevalence and nature of difficulty with sleep.
SLEEPSustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia
621 Citations2003Andrew D. Krystal, James K. Walsh +5 more
Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function, which is compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.
Archives of Internal MedicineClinical Correlates of Insomnia in Patients With Chronic Illness
471 Citations1998David A. Katz, Colleen A. McHorney
JAMABenzodiazepines and Zolpidem for Chronic Insomnia
451 Citations1997Peter D. Nowell
Benzodiazepines and zolpidem produced reliable improvements in commonly measured parameters of sleep in patients with chronic insomnia, and presented challenges for developing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.
Archives of General PsychiatryLong-term Therapeutic Use of Benzodiazepines
324 Citations1990Karl Rickels
A short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and neuroticism, less education and higher baseline levels of anxious and depressive symptoms.
Archives of General PsychiatryRecorded and Reported Sleep in Chronic Primary Insomnia
303 Citations1976Bernard L. Frankel
Current Medical Research and OpinionEfficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
294 Citations2004Gary Zammit, Louis J. McNabb +3 more
Patients treated with nightly eszopiclone 3 mg had better polysomnographic and patient-reported measures of sleep over the 6-week trial and no detrimental effects on next-day psychomotor performance using the DSST.
Postgraduate MedicineInsomnia and its treatment
293 Citations1984Robert Malcolm, John A. Gross
Symptomatic treatment of transient insomnias is advisable, for without treatment these sleep disorders may become persistent and the drugs of choice are the benzodiazepine hypnotics, which have minimal side effects when used for short periods in properly selected patients.
Journal of Consulting and Clinical PsychologyCognitive-behavior therapy for late-life insomnia.
235 Citations1993Charles M. Morin, Robert A. Kowatch +2 more
It is shown that late-life insomnia can be effectively treated with nonpharmacological interventions and that dysfunctional beliefs and attitudes about sleeplessness can be changed.
New England Journal of MedicineThe Diagnosis and Management of Insomnia
223 Citations1990J. Christian Gillin, William Byerley +2 more
The recent widow, the ruminative worrier, the sleepless patient with chronic obstructive pulmonary disease, the melancholic depressive person, and the executive with jet lag all share the condition of insomnia, but the cause of their problem and their therapeutic needs differ.
PubMedA multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
223 Citations1994Martin B. Scharf, Thomas Röth +2 more
10 mg of zolpidem was found to be safe and effective for the long-term treatment of chronic insomnia, demonstrating hypnotic efficacy without affecting sleep stages or producing tolerance effects, rebound effects, or detrimental effects on psychomotor performance.
Journal of the American Geriatrics SocietyPrevalence and Persistence of Sleep Complaints in a Rural Older Community Sample: The MoVIES Project
163 Citations1996Mary Ganguli, Charles F. Reynolds +1 more
To determine the prevalence and 2‐year persistence of subjective sleep complaints in a rural older population, a large sample of older people in rural areas is studied.
PubMedNew epidemiologic findings about insomnia and its treatment.
155 Citations1992Mitchell B. Balter, E. H. Uhlenhuth
In populations representative of everyday outpatient practice, it was found that the abuse liability of benzodiazepine hypnotics with shorter and longer elimination half-lives was generally low and comparable; and past-year prevalence rates for serious accidents/injuries were much higher for chronic untreated insomnia than for normal controls and most groups treated with psychotherapeutic medications.
Psychology Press eBooksEpidemiology of Sleep
138 Citations2013Kenneth L. Lichstein, H. Heith Durrence +3 more
An Archive of Normal Sleep and an Archive of Insomnia: An Archive of the Sleep of African Americans: A Review of Epidemiological Studies of Ins insomnia and Sleep.
Sleep MedicineA five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia
122 Citations2000James K. Walsh, Gerald W. Vogel +6 more
Zaleplon 10 mg is effective in the treatment of sleep onset insomnia over a period of 35 nights, with minimal evidence of undesired effects.
Age and AgeingFactors Influencing Persistent Subjective Insomnia in Old Age: a Follow-up Study of Good and Poor Sleepers aged 65 to 74
100 Citations1989Kevin Morgan, Diane W. Healey +1 more
Despite the existence of health problems as a major cause of sleep disturbance in later life, personality factors appear to exert a pervasive influence on subjective sleep quality among the 'younger' elderly.
BMJBenzodiazepine hypnotics remain effective for 24 weeks.
97 Citations1982Isabelle P. Oswald, Craig French +2 more
It is concluded that benzodiazepines remain effective for at least 24 weeks but that a period of disturbed sleep may be expected after withdrawal.
Age and AgeingLongitudinal trends in late-life insomnia: implications for prescribing
78 Citations1997Kevin Morgan, David D. Clarke
Outcomes at 4-year follow-up suggest that, for the majority of surviving cases identified in a prevalence screen and for a substantial minority of incident cases, late-life insomnia shows a level of chronicity incompatible with hypnotic drug therapy as currently recommended.
Journal of Psychopathology and Behavioral AssessmentUse of the Sleep Assessment Device (Kelley and Lichstein, 1980) to validate insomniacs' self-report of sleep pattern
26 Citations1989Colin A. Espie, William R. Lindsay +1 more